Tag: treatment

GEORGE TOWN, Cayman Islands, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water supply and treatment plants, reported results for the second quarter ended June 30, 2025. All comparisons are to the same prior year period unless otherwise noted.

PITTSBURGH, Aug. 11, 2025 (GLOBE NEWSWIRE) -- PhyNet Dermatology LLC (“PhyNet”) recently announced a cybersecurity incident involving its affiliate Total Vein & Skin, LLC d/b/a Premier Dermatology Partners (“TVS”), which impacted the personal information of an unknown number of individuals.¹ The information potentially impacted in the data breach includes individuals’ names, addresses, Social Security number, financial account information, date of birth, medical history information, treatment information, diagnosis information, treating physician, medical record number, and health insurance information.

Increased revenue 13% YoY and maintained sustained PAC price improvement

Langenfeld, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Booking Health, a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 Cervical Cancer Patients. The report outlines how cutting-edge immunotherapy is reshaping care for women with advanced cervical cancer, offering new pathways to longer survival and improved quality of life, particularly in cases resistant to standard treatments.

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $18 billion and $22 billion. This forecast reflects the company’s unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders.

COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2025 financial results on Thursday August 14, 2025, before opening of the Nasdaq CM.